Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 7:07 p.m.

    📋 BridgeBio Pharma, Inc. (BBIO) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 16:43:53

    Event Type: Financial Results

    Event Details:

    BridgeBio Pharma (BBIO) Reports Q3 2022 Financial Results BridgeBio Pharma (BBIO) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 9708
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 472646
      • expected in mid-2023
      • anticipated by year-end 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Revenue 54.02K 75.44K $-21.42K -28.39%
    Operating Costs And Expenses Research Development 102.07K 218.10K $-116.03K -53.20%
    Operating Costs And Expenses Selling General Administrative 45.97K 80.14K $-34.17K -42.64%
    Operating Costs And Expenses Restructuring Impairment 8.40K 31.06K $-22.66K -72.97%
    Total Operating Expenses 148.04K 329.29K $-181.25K -55.04%
    Loss From Operations 94.02K 253.85K $-159.84K -62.96%
    Other Income Expense Net Interest Income 323.00 1.03K $-710.00 -68.73%
    Other Income Expense Net Interest Expense 10.84K 40.62K $-29.78K -73.32%
    Total Other Income Expense 8.06K 49.97K $-41.91K -83.87%
    Net Loss 102.07K 203.89K $-101.81K -49.94%
    Net Loss Attributable Noncontrolling 5.73K 2.36K $3.36K +142.22%
    Net Loss Attributable Common Stockholders 96.35K 206.25K $-109.91K -53.29%
    Net Loss Per Share 0.66 1.41 $-0.75 -53.19%
    Weighted Average Shares 146.75M 146.29M $468.61K +0.32%
    Research Development 19.28K 22.91K $-3.62K -15.82%
    Selling General Administrative 12.75K 28.50K $-15.75K -55.27%
    Assets Cash Equivalents Marketable Securities 688.56K 787.51K $-98.95K -12.56%
    Assets Investment Equity Securities 27.14K 49.15K $-22.01K -44.78%
    Assets Receivable Licensing Collaboration 22.82K 19.75K $3.07K +15.56%
    Assets Prepaid Expenses Other Current Assets 32.75K 32.45K $308.00 +0.95%
    Assets Property Equipment Net 16.87K 30.07K $-13.19K -43.88%
    Assets Operating Lease Right Of Use Assets 12.85K 15.91K $-3.06K -19.22%
    Assets Intangible Assets Net 29.91K 44.93K $-15.03K -33.44%
    Assets Other Assets 31.32K 33.03K $-1.71K -5.16%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Accounts Payable 8.79K 11.88K $-3.09K -26.01%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Operating Lease Liabilities 18.59K 22.37K $-3.78K -16.90%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Notes 734.05K 733.12K $928.00 +0.13%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Notes 540.78K 539.93K $845.00 +0.16%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Term Loans 418.35K 430.75K $-12.40K -2.88%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Other Long Term Liabilities 28.63K 22.07K $6.56K +29.73%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Redeemable Convertible Noncontrolling Interests 1.50K 1.42K $76.00 +5.34%
    Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Noncontrolling Interests 12.02K 3.41K $8.61K +252.23%
    Operating Activities Net Loss 203.89K 273.16K $-69.27K -25.36%
    Changes In Operating Assets And Liabilities Receivable Licensing Collaboration 2.99K 35.36K $-32.37K -91.54%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 3.02K 1.40K $1.62K +115.79%
    Changes In Operating Assets And Liabilities Other Assets 8.69K 5.72K $2.97K +51.86%
    Changes In Operating Assets And Liabilities Accounts Payable 3.09K 13.03K $-9.94K -76.28%
    Changes In Operating Assets And Liabilities Operating Lease Liabilities 3.35K 2.78K $572.00 +20.61%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BridgeBio Pharma
    • CIK: 0001743881
    • Ticker Symbol: BBIO
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories